GlobeNewswire PharmaOriginal article
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Phase 2positiveTNX-4800Positive
AI Analysis
Summary
Tonix Pharmaceuticals announced positive feedback from a Type C FDA meeting regarding the adaptive Phase 2 study design for TNX-4800, an anti-OspA monoclonal antibody for Lyme disease prevention, with planned study initiation in Q1 2027.
Clinical Trial Data
Phase
Phase 2
Outcome Details
Positive minutes from Type C FDA meeting with alignment on key study design elements
Importance:6/10
Sentiment:
0.75
FDA meetingType C meetingLyme diseasemonoclonal antibodyPhase 2 initiation
Read the original article
Published by GlobeNewswire Pharma on August 3, 2026 11:00 AM